IONIS PHARMACEUTICALS INC (IONS)
US4622221004 - Common Stock
Friday 12/27 Insider Buying Report: VTYX, IONS
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved TRYNGOLZA™ (olezarsen)...
Investors Snatch IONS 11.4% Lower Than Its Secondary Stock Offering
RSI Alert: Ionis Pharmaceuticals (IONS) Now Oversold
Ionis to present at upcoming investor conferences
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pivotal Phase 3 study design following successful alignment with the U.S. Food...
Ionis reports third quarter 2024 financial results
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024....
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New...
Ionis to hold third quarter 2024 financial results webcast
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern...
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for...
Interesting IONS Put And Call Options For December 20th
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Ionis Pharmaceuticals Enters Oversold Territory (IONS)
New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE)...
Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted zilganersen Fast Track...
January 2027 Options Now Available For Ionis Pharmaceuticals (IONS)
January 2026 Options Now Available For Ionis Pharmaceuticals
Investors Snatch IONS Even Cheaper Than Its Secondary Stock Offering
IONS Crosses Below Key Moving Average Level
Ionis announces pricing of $500.3 million public offering
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common...
Ionis announces proposed public offering of common stock
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a proposed underwritten public offering of $500.0 million of its common stock. Ionis...
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
Ionis to present at upcoming investor conferences
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor...
Ionis reports second quarter 2024 financial results
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial results for the second quarter of 2024....
Noteworthy Thursday Option Activity: SKX, STWD, IONS
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
Biogen previously decided against opting into Ionis' Angelman program.